Using immune scores and radiomics to improve staging in nasopharyngeal carcinoma

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to develop an immune score-based radiomic staging system for nasopharyngeal carcinoma (NPC) to enhance prognostic accuracy. Currently, the TNM staging system is used, but it does not account for the variability in patient outcomes with similar stages. By integrating immune scores with radiomic data, the study seeks to provide a more personalized assessment of prognosis and treatment strategies for NPC patients. The study will involve patients with newly confirmed non-keratinizing or keratinizing carcinoma and will assess their immune profiles alongside imaging data.

Why it matters

Who can join: the full rules

Inclusion Criteria:

Patients with newly histologically confirmed non-keratinizing/keratinizing carcinoma.

ECOG Performance status: 0-1 With normal liver function test (ALT, AST ≤2.5ULN) Renal: creatinine clearance ≥60ml/min Without hematopathy,marrow: WBC \>4\*109/L, HGB\>90G/L, and PLT\>100\*109/L. Written informed consent

Exclusion Criteria:

Contraindications for MRI scan Prior malignancy (except adequately treated carcinoma in-situ of the cervix or · basal/squamous cell carcinoma of the skin) Previous chemotherapy or radiotherapy (except non-melanomatous skin cancers outside the intended RT treatment volume) Patient is pregnant or lactating Any severe intercurrent disease, which may bring unacceptable risk or affect the compliance of the trial, for example, unstable cardiac disease requiring treatment, renal disease, chronic hepatitis, diabetes with poor control (fasting plasma glucose \>1.5×ULN), or emotional disturbance.

Where it's running

• Renmin Hospital of Wuhan University
  Wuhan, Hubei, China Recruiting
• Ningbo First Hospital
  Ningbo, Ningbo, China Recruiting
• Ningbo Medical Center Lihuili Hospital
  Ningbo, Ningbo, China Recruiting
• The First Affiliated Hospital of Wenzhou Medical University
  Wenzhou, Wenzhou, China Recruiting
• Zhejiang Cancer Hospital
  Hangzhou, Zhejiang, China Recruiting

Study contacts

• Principal investigator: Xiaozhong Chen — Department of Radiation Oncology, Zhejiang Cancer Hospital
• Study coordinator: Xiaozhong Chen
• Email: cxzfyun@sina.com
• Phone: 0571-88128202

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Docetaxel and SX-682 in head and neck cancers and prostate cancer

  This trial tests a new drug SX-682 together with docetaxel in adults whose head and neck cancers or prostate cancer have returned or spread.

  Recruiting Phase 1/2 National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT07667400

• Becotatug Vedotin for EGFR-positive relapsed, refractory, or metastatic pediatric solid tumors

  This trial will test Becotatug Vedotin, an EGFR-targeted antibody-drug conjugate, to see if it is safe and helps children aged 2–18 with EGFR-positive relapsed, refractory, or metastatic solid tumors.

  Recruiting Phase 1 Sun Yat-sen University · Guangzhou, Guangdong · NCT07584499

• Induction and maintenance with MRG003, Tislelizumab, and Capecitabine for locally recurrent nasopharyngeal cancer

  This study tests a treatment combo of MRG003 and a PD-1 blocker first, then continues with Capecitabine plus the PD-1 blocker to see if it helps patients with locally recurrent NPC.

  Recruiting Phase 2 Fujian Cancer Hospital · Fuzhou, Fujian · NCT07331428

• Lower-dose (40.2 Gy) versus standard-dose (49.2 Gy) radiotherapy to low‑risk areas for chemosensitive Stage II nasopharyngeal cancer

  This trial will try a lower radiotherapy dose (40.2 Gy) instead of the standard 49.2 Gy for people with stage II nasopharyngeal cancer who had a strong response to induction chemo and have undetectable EBV DNA.

  Recruiting at 15 sites Phase 3 Sun Yat-sen University · Hefei, Anhui and 14 other locations · NCT07328854

• Screening for early nasopharyngeal (nose) cancer

  This project tests whether blood and saliva markers can find nasopharyngeal cancer early in adults aged 35 to 60 who are at higher risk because of ethnicity or family history.

  Recruiting at 2 sites National University Hospital, Singapore · Singapore and 1 other locations · NCT07019870

• Proton versus photon radiation for nasopharyngeal cancer

  This trial will test whether proton radiation works at least as well as standard photon radiation for adults newly diagnosed with nasopharyngeal cancer that has not spread.

  Recruiting Phase 3 Shandong Cancer Hospital and Institute · Jinan · NCT07000643

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.